Skip to content
Screener

Organon OGN Q1 2026 earnings

Reported April 30, 2026 · Before market open

Revenue$1.5BMiss by $27.5M
EPS$0.71Miss by $0.12
Revenue estimate$1.5B
EPS estimate$0.83

Next report

Nov 9, 2026 (in a month)
Revenue estimate$1.6B
EPS estimate$0.88

Financials

Q1 2026

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.56B-59.4%
Enterprise value$9.01B-26.4%
P/S0.3×-0.4×

Profitability

See full
Gross margin52.8%-4.4pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Segments

By product

See full
Nexplanon/Implanon NXT$201.0M-19.0%
Other$87.0M+11.5%
Zetia$87.0M+2.4%
Atozet$85.0M+10.4%
Other Non-Opiod Pain, Bone and Dermatology$68.0M0.0%

By geography

See full
Europe and Canada$412.0M+9.6%
Latin America, Middle East, Russia, and Africa$247.0M+2.9%
Asia Pacific and Japan$226.0M-10.0%
Other$23.0M-23.3%

FAQ

When did Organon report Q1 2026 earnings?
Organon (OGN) reported Q1 2026 earnings on April 30, 2026 before market open.
What were Organon's Q1 2026 revenue and EPS?
Organon reported revenue of $1.5B and eps of $0.71 for Q1 2026.
Did Organon beat estimates in Q1 2026?
Revenue missed the consensus estimate of $1.5B by $27.5M. EPS missed the consensus estimate of $0.83 by $0.12.
How did Organon's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 3.5% from $1.5B a year earlier and eps declined 30.4% from $1.02.
Where can I find Organon's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-178718) and the 10-Q periodic report (0001628280-26-029532) directly on SEC EDGAR. The filing index links above go to sec.gov.